Ribomic

Ribomic EBIT per Employee

The EBIT per Employee of Ribomic (4591.T) as of Oct 30, 2026 is -48.29 M JPY. In the previous year, EBIT per Employee was -42.02 M JPY — a change of 14.90% (lower).

EBIT per Employee

-48.29 MJPY

YoY

14.90%

Last updated:

EBIT per Employee of Ribomic is 2026 -48.29 M JPY. EBIT per Employee of Ribomic was 2025 -42.02 M JPY. It decreases by 14.90% lower compared to the previous year.

The Ribomic EBIT per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Employee
Date
EBIT per Employee
Jan 1, 2019
-37.15 M JPY
Jan 1, 2020
-36.58 M JPY
Jan 1, 2021
-49.59 M JPY
Jan 1, 2022
-69.92 M JPY
Jan 1, 2023
-71.44 M JPY
Jan 1, 2024
-44.65 M JPY
Jan 1, 2025
-42.02 M JPY
Jan 1, 2026
-48.29 M JPY
The Ribomic EBIT per Employee history
YEAREBIT per EmployeeYoY
-48.29 MJPY+14.90%
-42.02 MJPY-5.88%
-44.65 MJPY-37.50%
-71.44 MJPY+2.17%
-69.92 MJPY+41.02%
-49.59 MJPY+35.54%
-36.58 MJPY-1.51%
-37.15 MJPY+3.19%
-36.00 MJPY+14.50%
-31.44 MJPY+47.62%
-21.30 MJPY-8,714.71%
247,200.00JPY-101.05%
-23.62 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Ribomic Stock analysis

What does Ribomic do? Ribomic, Inc. engages in the research and development of molecular targeted drugs using Ribonucleic Acid (RNA) aptamers for therapeutic applications. Headquartered in Minato-Ku, Tokyo-To, the company utilizes its workforce of 25 full-time employees to drive its drug discovery operations, which are structured into self discovery and co-discovery divisions. This operational framework allows the firm to focus on advancing RNA aptamer technologies for medical use. The Self Drug Discovery division develops aptamers and licenses these results to pharmaceutical companies, generating revenue through intellectual property transfers. Meanwhile, the Co-Discovery division collaborates with alliance pharmaceutical companies researching aptamer pharmaceuticals. This segment earns research expenses paid by the alliance partners for the shared portion of the co-discovery business, creating a dual revenue stream based on licensing and collaborative research fees. Ribomic is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Ribomic stock

EBIT per Employee of Ribomic is -48.29 M JPY in 2026.

EBIT per Employee of Ribomic changed from -42.02 M JPY to -48.29 M JPY, representing a 14.90% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Employee Ribomic since 2006 – with annual values, charts, and detailed analysis.

EBIT per employee measures operating profit per employee, showing how efficiently the workforce generates operating earnings.

EBIT per Employee's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT per Employee's Ribomic historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Ribomic

All Key Metrics — Ribomic